Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kodiak Sciences Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise. Following the transaction, he directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this filing, and the derivative position tied to this specific option grant has been fully converted into common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
300,000 shares exercised/converted
Mixed
2 txns
Insider
PERLROTH VICTOR
Role
Chairman and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 300,000 | $0.00 | -- |
| Exercise | Common Stock | 300,000 | $1.04 | $312K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 2,395,538 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Kodiak Sciences (KOD) report for Victor Perlroth?
Kodiak Sciences reported that Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at $1.0400 per share. The transaction converts previously granted options into shares, without indicating any open-market sale in this filing.
What was the nature of the derivative transaction reported for Kodiak Sciences?
The filing reports an option exercise classified as an exercise or conversion of a derivative security. A fully vested stock option covering 300,000 underlying shares of Common Stock was exercised at an exercise price of $1.0400, eliminating that option position and increasing direct share ownership.
Are the stock options exercised by Victor Perlroth in Kodiak Sciences fully vested?
Yes. A footnote states that the shares subject to this option are fully vested. This means the 300,000 options exercised at $1.0400 per share were already earned under the grant terms before being converted into Common Stock on March 25, 2026.
Does this Kodiak Sciences Form 4 show any remaining derivative holdings for Victor Perlroth?
The derivative summary in the data is empty, and the option entry shows zero shares following the transaction, indicating this specific 300,000-share option grant has been fully exercised, with no remaining derivative position from that grant reflected in this filing.